Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

Allinen, 2004, Molecular characterization of the tumor microenvironment in breast cancer, Cancer Cell, 6, 17, 10.1016/j.ccr.2004.06.010

Ashwell, 2008, DNA damage detection and repair pathways–recent advances with inhibitors of checkpoint kinases in cancer therapy, Clin. Cancer Res., 14, 4032, 10.1158/1078-0432.CCR-07-5138

Bartkova, 2005, DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis, Nature, 434, 864, 10.1038/nature03482

Bartkova, 2006, Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints, Nature, 444, 633, 10.1038/nature05268

Bonnet, 2007, A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth, Cancer Cell, 11, 37, 10.1016/j.ccr.2006.10.020

Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443

Cahill, 1998, Mutations of mitotic checkpoint genes in human cancers, Nature, 392, 300, 10.1038/32688

2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385

Carlo-Stella, 2007, Targeting TRAIL agonistic receptors for cancer therapy, Clin. Cancer Res., 13, 2313, 10.1158/1078-0432.CCR-06-2774

Carpinelli, 2008, Aurora kinases and their inhibitors: more than one target and one drug, Adv. Exp. Med. Biol., 610, 54, 10.1007/978-0-387-73898-7_5

Chen, 2006, Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics, Int. J. Cancer, 119, 2784, 10.1002/ijc.22198

Chin, 1999, Essential role for oncogenic Ras in tumour maintenance, Nature, 400, 468, 10.1038/22788

Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734

Collins, 2007, Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map, Nature, 446, 806, 10.1038/nature05649

Conde, 2001, Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice, EMBO J., 20, 3535, 10.1093/emboj/20.13.3535

Dai, 2007, Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis, Cell, 130, 1005, 10.1016/j.cell.2007.07.020

DeBerardinis, 2007, Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis, Proc. Natl. Acad. Sci. USA, 104, 19345, 10.1073/pnas.0709747104

DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metab., 7, 11, 10.1016/j.cmet.2007.10.002

Denko, 1994, The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle, Proc. Natl. Acad. Sci. USA, 91, 5124, 10.1073/pnas.91.11.5124

Denoyelle, 2006, Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway, Nat. Cell Biol., 8, 1053, 10.1038/ncb1471

Dewhirst, 2008, Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response, Nat. Rev. Cancer, 8, 425, 10.1038/nrc2397

Di Micco, 2006, Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication, Nature, 444, 638, 10.1038/nature05327

Dickins, 2007, Tissue-specific and reversible RNA interference in transgenic mice, Nat. Genet., 39, 914, 10.1038/ng2045

Diehn, 2009, Association of reactive oxygen species levels and radioresistance in cancer stem cells, Nature, 10.1038/nature07733

Dikmen, 2005, In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor, Cancer Res., 65, 7866, 10.1158/0008-5472.CAN-05-1215

Ding, 2008, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, 455, 1069, 10.1038/nature07423

Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969

Druker, 2002, Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML, Oncogene, 21, 8541, 10.1038/sj.onc.1206081

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655

Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445

Felsher, 1999, Reversible tumorigenesis by MYC in hematopoietic lineages, Mol. Cell, 4, 199, 10.1016/S1097-2765(00)80367-6

Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat. Rev. Drug Discov., 3, 391, 10.1038/nrd1381

Fiorentini, 2006, Hyperthermia today: electric energy, a new opportunity in cancer treatment, J. Cancer Res. Ther., 2, 41, 10.4103/0973-1482.25848

Folkman, 2007, Angiogenesis: an organizing principle for drug discovery?, Nat. Rev. Drug Discov., 6, 273, 10.1038/nrd2115

Ganem, 2007, Tetraploidy, aneuploidy and cancer, Curr. Opin. Genet. Dev., 17, 157, 10.1016/j.gde.2007.02.011

Garrido, 2001, MHC antigens and tumor escape from immune surveillance, Adv. Cancer Res., 83, 117, 10.1016/S0065-230X(01)83005-0

Gogvadze, 2008, Mitochondria in cancer cells: what is so special about them?, Trends Cell Biol., 18, 165, 10.1016/j.tcb.2008.01.006

Gorgoulis, 2005, Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions, Nature, 434, 907, 10.1038/nature03485

Greenman, 2007, Patterns of somatic mutation in human cancer genomes, Nature, 446, 153, 10.1038/nature05610

Guertin, 2007, Defining the role of mTOR in cancer, Cancer Cell, 12, 9, 10.1016/j.ccr.2007.05.008

Hahn, 2002, Modelling the molecular circuitry of cancer, Nat. Rev. Cancer, 2, 331, 10.1038/nrc795

Halazonetis, 2008, An oncogene-induced DNA damage model for cancer development, Science, 319, 1352, 10.1126/science.1140735

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

Harley, 2008, Telomerase and cancer therapeutics, Nat. Rev. Cancer, 8, 167, 10.1038/nrc2275

Harper, 2007, The DNA damage response: ten years after, Mol. Cell, 28, 739, 10.1016/j.molcel.2007.11.015

Hartwell, 1994, Cell cycle control and cancer, Science, 266, 1821, 10.1126/science.7997877

Hu, 2008, Microenvironmental regulation of cancer development, Curr. Opin. Genet. Dev., 18, 27, 10.1016/j.gde.2007.12.006

Huettner, 2000, Reversibility of acute B-cell leukaemia induced by BCR-ABL1, Nat. Genet., 24, 57, 10.1038/71691

Hynes, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat. Rev. Cancer, 5, 341, 10.1038/nrc1609

Iida, 1997, Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma, Nat. Genet., 17, 226, 10.1038/ng1097-226

Jain, 2002, Sustained loss of a neoplastic phenotype by brief inactivation of MYC, Science, 297, 102, 10.1126/science.1071489

Jin, 2007, Role of autophagy in cancer: management of metabolic stress, Autophagy, 3, 28, 10.4161/auto.3269

Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368

Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat. Rev. Cancer, 5, 689, 10.1038/nrc1691

Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186

Karnoub, 2007, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, Nature, 449, 557, 10.1038/nature06188

Kennedy, 2007, Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated, J. Clin. Invest., 117, 1440, 10.1172/JCI31245

Kim, 1993, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, 362, 841, 10.1038/362841a0

Komarova, 2002, Dynamics of genetic instability in sporadic and familial colorectal cancer, Cancer Biol. Ther., 1, 685, 10.4161/cbt.321

Kroemer, 2008, Tumor cell metabolism: cancer's Achilles' heel, Cancer Cell, 13, 472, 10.1016/j.ccr.2008.05.005

Lee, 1999, Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species, J. Biol. Chem., 274, 7936, 10.1074/jbc.274.12.7936

Lee, 2006, Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human, Cell Cycle, 5, 2110, 10.4161/cc.5.18.3218

Longley, 2003, 5-fluorouracil: mechanisms of action and clinical strategies, Nat. Rev. Cancer, 3, 330, 10.1038/nrc1074

Maira, 2008, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol. Cancer Ther., 7, 1851, 10.1158/1535-7163.MCT-08-0017

Martins, 2006, Modeling the therapeutic efficacy of p53 restoration in tumors, Cell, 127, 1323, 10.1016/j.cell.2006.12.007

Maser, 2002, Connecting chromosomes, crisis, and cancer, Science, 297, 565, 10.1126/science.297.5581.565

Mathew, 2007, Autophagy suppresses tumor progression by limiting chromosomal instability, Genes Dev., 21, 1367, 10.1101/gad.1545107

McGuire, 2003, Anticancer antifolates: current status and future directions, Curr. Pharm. Des., 9, 2593, 10.2174/1381612033453712

Moreira, 2006, Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality, Rev. Recent Clin. Trials, 1, 217, 10.2174/157488706778250050

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 24, 16, 10.1200/JCO.2005.02.2574

Muller, 2006, Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors, Nat. Rev. Cancer, 6, 613, 10.1038/nrc1929

Nava-Parada, 2007, GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers, Curr. Opin. Mol. Ther., 9, 490

Ngo, 2006, A loss-of-function RNA interference screen for molecular targets in cancer, Nature, 441, 106, 10.1038/nature04687

Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034

Papp, 2003, Dosage sensitivity and the evolution of gene families in yeast, Nature, 424, 194, 10.1038/nature01771

Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382

Peggs, 2008, Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy, Immunol. Rev., 224, 141, 10.1111/j.1600-065X.2008.00649.x

Pelengaris, 1999, Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion, Mol. Cell, 3, 565, 10.1016/S1097-2765(00)80350-0

Pollack, 2002, Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors, Proc. Natl. Acad. Sci. USA, 99, 12963, 10.1073/pnas.162471999

Pommier, 2006, Topoisomerase I inhibitors: camptothecins and beyond, Nat. Rev. Cancer, 6, 789, 10.1038/nrc1977

Pouyssegur, 2006, Hypoxia signalling in cancer and approaches to enforce tumour regression, Nature, 441, 437, 10.1038/nature04871

Qiu, 2008, No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas, Nat. Genet., 40, 650, 10.1038/ng.117

Quintas-Cardama, 2007, Flying under the radar: the new wave of BCR-ABL inhibitors, Nat. Rev. Drug Discov., 6, 834, 10.1038/nrd2324

Richardson, 2006, Bortezomib: proteasome inhibition as an effective anticancer therapy, Annu. Rev. Med., 57, 33, 10.1146/annurev.med.57.042905.122625

Roberts, 2007, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene, 26, 3291, 10.1038/sj.onc.1210422

Roccaro, 2006, Bortezomib as an antitumor agent, Curr. Pharm. Biotechnol., 7, 441, 10.2174/138920106779116865

Sakai, 2008, Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers, Nature, 451, 1116, 10.1038/nature06633

Schlabach, 2008, Cancer proliferation gene discovery through functional genomics, Science, 319, 620, 10.1126/science.1149200

Selivanova, 2007, Reactivation of mutant p53: molecular mechanisms and therapeutic potential, Oncogene, 26, 2243, 10.1038/sj.onc.1210295

Shaffer, 2008, IRF4 addiction in multiple myeloma, Nature, 454, 226, 10.1038/nature07064

Sharma, 2005, Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer, Cancer Res., 65, 5211, 10.1158/0008-5472.CAN-05-0141

Sharma, 2007, Oncogene addiction: setting the stage for molecularly targeted cancer therapy, Genes Dev., 21, 3214, 10.1101/gad.1609907

Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat. Rev. Cancer, 7, 169, 10.1038/nrc2088

Shirasawa, 1993, Altered growth of human colon cancer cell lines disrupted at activated Ki-ras, Science, 260, 85, 10.1126/science.8465203

Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933

Silva, 2008, Profiling essential genes in human mammary cells by multiplex RNAi screening, Science, 319, 617, 10.1126/science.1149185

Sjoblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427

Solimini, 2007, Non-oncogene addiction and the stress phenotype of cancer cells, Cell, 130, 986, 10.1016/j.cell.2007.09.007

Spira, 2003, Differentiation therapy, Curr. Opin. Pharmacol., 3, 338, 10.1016/S1471-4892(03)00081-X

Stauffer, 2007, Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737, Curr. Top. Med. Chem., 7, 961, 10.2174/156802607780906843

Stolina, 2000, Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis, J. Immunol., 164, 361, 10.4049/jimmunol.164.1.361

Storchová, 2006, Genome-wide genetic analysis of polyploidy in yeast, Nature, 443, 541, 10.1038/nature05178

Strebhardt, 2006, Targeting polo-like kinase 1 for cancer therapy, Nat. Rev. Cancer, 6, 321, 10.1038/nrc1841

Su, 2005, Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer, J. Immunol., 174, 3798, 10.4049/jimmunol.174.6.3798

Szatrowski, 1991, Production of large amounts of hydrogen peroxide by human tumor cells, Cancer Res., 51, 794

Torres, 2007, Effects of aneuploidy on cellular physiology and cell division in haploid yeast, Science, 317, 916, 10.1126/science.1142210

Torres, 2008, Aneuploidy: cells losing their balance, Genetics, 179, 737, 10.1534/genetics.108.090878

Tsafrir, 2006, Relationship of gene expression and chromosomal abnormalities in colorectal cancer, Cancer Res., 66, 2129, 10.1158/0008-5472.CAN-05-2569

Vander Heiden, 2001, Growth factors can influence cell growth and survival through effects on glucose metabolism, Mol. Cell. Biol., 21, 5899, 10.1128/MCB.21.17.5899-5912.2001

Vassilev, 2007, MDM2 inhibitors for cancer therapy, Trends Mol. Med., 13, 23, 10.1016/j.molmed.2006.11.002

Ventura, 2007, Restoration of p53 function leads to tumour regression in vivo, Nature, 445, 661, 10.1038/nature05541

Verdine, 2007, The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members, Clin. Cancer Res., 13, 7264, 10.1158/1078-0432.CCR-07-2184

Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309

Weaver, 2005, Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death, Cancer Cell, 8, 7, 10.1016/j.ccr.2005.06.011

Weinstein, 2002, Cancer. Addiction to oncogenes–the Achilles heal of cancer, Science, 297, 63, 10.1126/science.1073096

Weinstein, 2008, Oncogene addiction, Cancer Res., 68, 3077, 10.1158/0008-5472.CAN-07-3293

Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001, 10.1038/nature06526

Whitesell, 2005, HSP90 and the chaperoning of cancer, Nat. Rev. Cancer, 5, 761, 10.1038/nrc1716

Williams, 2008, Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells, Science, 322, 703, 10.1126/science.1160058

Windle, 1991, A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration, Genes Dev., 5, 160, 10.1101/gad.5.2.160

Wood, 2007, The genomic landscapes of human breast and colorectal cancers, Science, 318, 1108, 10.1126/science.1145720

Xue, 2007, Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, 445, 656, 10.1038/nature05529

Yang, 2008, Nf1-dependent tumors require a microenvironment containing Nf1+/−- and c-kit-dependent bone marrow, Cell, 135, 437, 10.1016/j.cell.2008.08.041

Zou, 2005, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat. Rev. Cancer, 5, 263, 10.1038/nrc1586